Post-Marketing Experience 1983–86

| Home | | Pharmacovigilance |

Chapter: Pharmacovigilance: Nomifensine and Haemolytic Anaemia

The increasing incidence of haemolytic anaemia from 1983 might appear to have been related to the launch of the 100 mg single daily dose formulation on 31 January 1983.


The increasing incidence of haemolytic anaemia from 1983 might appear to have been related to the launch of the 100 mg single daily dose formulation on 31 January 1983 (Figure 11.1). However, no evidence emerged to support this. It appears that new additional sales were generated by this launch and that the asso-ciated promotion may have made doctors more aware of nomifensine. Prescriptions, sales and market share increased in 1983 by 21%, 32% and 18%, respec-tively. This, together with the data sheet changes and literature reports, may have served to alert doctors to the association of unusual symptoms with the use of nomifensine.

Reports of other severe untoward events that could have had an immunological basis also appeared in the literature in 1984–85: thrombocytopenia (Green et al., 1984), hepatitis (Vaz et al., 1984), alveolitis (Hamm et al., 1985) and a systemic lupus erythematosus (SLE)-like reaction (Garcia-Morteo and Maldonado-Cocco, 1983; Schönhöfer and Groticke, 1985). Those appearing in the British medical literature could possibly have contributed to an increased awareness amongst prescribers of adverse events associated with the drug. The first fatal case of immune haemolysis was published in 1985 (Sokol et al., 1985), and two other cases were reported later the same year (Hamm et al., 1985; Schönhöfer and Groticke, 1985).

In the early to mid-1980s following the withdrawal of benoxaprofen and the recognition of problems with other non-steroidal anti-inflammatory drugs, together with promotion of the government’s Yellow Card scheme, there was an increasing acceptance amongst doctors of the need to report adverse experiences with commonly prescribed drugs. In September 1983, the antidepressant zimeldine was withdrawn from the market following the identification of a serious neurological disorder, the Guillain–Barré syndrome. The publicity given to this may have affected the reporting of adverse events to drug therapy, including nomifensine.

The purpose of showing the comparative incidences of fever, hepatic reactions and haemolytic anaemia in Figure 11.2 is not to suggest any common underly-ing pathology to these three conditions; none has ever been substantiated. It is to indicate that, whilst report-ing rates of haemolytic anaemia and hepatic problems (enzyme changes, jaundice or hepatitis) significantly increased with time, this was not the case with reports of febrile reactions. The incidence of these never reached the same levels as in some other countries, e.g. Germany. Cases in the United Kingdom in which fever was associated with haemolysis were catalogued in the haemolytic anaemia group.

Table 11.2 shows the UK manufacturer’s total database of 296 events; this is to be compared with the CSM’s Yellow Card database of 543 suspected adverse reactions. The company had 45 reports of haemolytic anaemia of which 43 were thought to be associated with the drug. This is to be compared with the CSM’s 59 reports of which 49 contained suffi-cient information to attribute nomifensine as the prob-able, or a possible, cause. Forty-five of the 49 (92%) patients were women, although females received only 71% of the prescriptions for the drug. Some of the subjects, who had had a previous course of nomifensine without experiencing unwanted effects, developed acute haemolytic anaemia on recommenc-ing treatment, whereas others developed haemolytic anaemia after months or years of continuous use. In 18 patients, the haemolysis was severe: 11 of them devel-oped renal failure and 4 died. Although haemolytic anaemia was the most frequently reported serious adverse reaction, concern was also expressed over other untoward effects (CSM Update, 1986).

From 1983 onwards, there was a steady rise in the number of reports of haemolytic anaemia to the UK manufacturer, with 5 reports in 1983, 12 in 1984 and 18, including 3 fatalities, in 1985. The first nomifensine-associated fatality in the United King-dom was reported on 10 February, the second was reported on 31 March and the third on 10 April 1985. The three cases were discussed with the DHSS on 1 May 1985.

The first of these fatal cases was published in the British Medical Journal in August 1985 (Sokol et al., 1985). The patient was a 36-year-old female who collapsed 1 h after taking one 100 mg tablet. She had been treated with nomifensine for 1 week but stopped taking it because of dizziness. There was no jaundice or haematuria. On examination, she was conscious but pale, cyanosed and shocked. Her blood pressure was 90/50 mmHg, and her pulse was 90/min. Haematological tests showed spontaneous red cell agglutination, with free haemoglobin in the plasma, and the following results: haemoglobin 5 g/dl, biliru-bin 4 mol/l and lactate dehydrogenase 1071 IU/l. The patient had severe acidosis. Acute intravascular haemolysis was diagnosed. Attempts at resuscitation failed, and the patient died. Immunological investiga-tions showed a positive Coombs’ test with antisera to IgG, IgM and Cl. The serum contained cold-reacting auto-antibodies and pan antibodies. In the presence of nomifensine, the antibodies led to the agglutination of red cells.

The proposed mechanism was that drug and anti-body combined to form loose immune complexes that attached themselves to the red cells and activated complement. Complement activation led to haemol-ysis, disseminated intravascular coagulation and the shock-lung syndrome.

Between January 1983 and mid-June 1985, the DHSS was aware of 29 reports of haemoly-sis in 592,000 prescriptions—approximately one in 1:20,000 prescriptions (CSM Update, 1986).

In July 1985, the CSM’s bulletin, Current Prob-lems, highlighted the dangers of newer antidepressants and presented a summary of adverse drug reactions to nomifensine. A new data sheet was published with information submitted in October 1984. This stated that :

In rare cases, haemolytic anaemia and abnormal liver function tests with or without clinical jaundice have been observed. These reactions subside within a short time of discontinuing Merital (nomifensine) but may recur if it is taken again.

In September 1985, there were joint discussions between the company and the DHSS on a complete revision of the data sheet. On 24 September, the current data sheet was put in abeyance pending the outcome of these discussions and all promotion of nomifensine ceased.

On 30 September 1985, the company issued a ‘Dear Doctor’ letter warning of the serious adverse reactions reported internationally; this letter was a version of a similar ‘Red Hand’ letter issued at the same time by the parent company in Germany.

On 7 December 1985, the ‘CSM Update’ on antide-pressants, published in the British Medical Journal, summarised the comparative adverse reaction reports on all antidepressants (CSM Update, 1985).

On 16 December 1985, the Drug and Thera-peutics Bulletin published an article ‘Trouble with nomifensine’ after several revisions since the first draft in May. This was followed by many newspaper reports on the drug.

Between mid-June and the end of November 1985, the DHSS was aware of 25 reports of haemolysis in 96,000 prescriptions (1:4000; CSM Update, 1986). This was the first time that the incidence had increased to a level above 1:10,000 (the accepted WHO defi-nition of a rare incidence), giving rise to a situation in which the benefits of the drug could no longer be said to outweigh the risks of haemolytic anaemia.

Four further cases of haemolytic anaemia were reported to the company in January 1986. One of these patients subsequently died. The UK data contributed to the ongoing appraisal of nomifensine being under-taken by the parent company, and this led to the product’s withdrawal from worldwide markets on 22 January 1986.

Table 11.3 summarises the events and assessments leading to the withdrawal of nomifensine 10 years after its first market launch.

Contact Us, Privacy Policy, Terms and Compliant, DMCA Policy and Compliant

TH 2019 - 2025; Developed by Therithal info.